# Using Data for Strategic Clarity: Questions to Ask

Source: https://www.keypedia.com/media/using-keypedia-for-strategic-clarity
Type: tutorial
Published: May 19, 2026
Authors: George Kwiecinski

> The right regulatory data is only useful if you ask the right questions. A short guide for quality leaders, biotech execs, and boards on what to ask, and where.

---

Most teams have more regulatory data than ever. Strategic clarity does not come from the data, it comes from the questions you bring to it.

![Screenshot 2026-05-19 at 11.21.31 AM.png](https://storage.googleapis.com/gks-blog-images/blog-images/da0db1a28077463ba5ed18597fde01fc.png)
*Paste any of these questions directly into the search on GKS, or sign in and navigate to KeyPedia or the Dashboard AI search.*

## For Heads of Quality and Regulatory Leaders

You own inspection readiness, supplier oversight, and CAPA effectiveness. Ask:

- > Which of my suppliers have active 483s or warning letters tied to my product class?
- > What citation patterns are repeating across my modality this year?
- > Which of my critical sites is trending in the wrong direction? A __[KRA score](https://www.globalkeysolutions.net/media/what-is-a-kra-score)__ over time answers this in one view.

## For Executives Managing Biotechs

Software is expensive. Consulting is more expensive. Lawyers are most expensive.

Use SaaS to cut through these costs. Grant your legal and consulting teams KeyPedia access and save their hours for the analysis that actually needs a human. Ask:

- > Where are the gaps in other 510(k) reviews for my device class?
- > What was the PAI inspection outcome for facilities with recent cell and gene therapy BLA applications?
- > Which CMOs in my modality have a clean enforcement record over the last 36 months?
- > What does the warning letter trend look like across my therapeutic area this year?

## For Boards and Investors, Critical Diligence

You are sizing regulatory exposure across a portfolio, a pipeline, or an acquisition target. Ask:

- > What percent of our pipeline value depends on suppliers with active enforcement?
- > How concentrated is our supplier base by jurisdiction and modality?
- > What is the regulatory risk profile of the acquisition target's full facility footprint?
- > Are we exposed to recently sanctioned sites, even one layer deep in the supply chain?

---

The right answers are not always comfortable, but by combining datasets, clarity unlocks **smarter data and safer decisions**. 

[Request a demo](https://www.globalkeysolutions.net/request-demo) or [browse KeyPedia Lite](https://www.globalkeysolutions.net/browse) to start asking these questions against live data.